Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avidity Biosciences, Inc.

69.80
-0.0500-0.07%
Post-market: 69.61-0.1900-0.27%19:37 EST
Volume:6.04M
Turnover:421.32M
Market Cap:10.26B
PE:-19.57
High:69.88
Open:69.77
Low:69.75
Close:69.85
52wk High:70.51
52wk Low:21.51
Shares:147.00M
Float Shares:113.00M
Volume Ratio:0.21
T/O Rate:5.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5671
EPS(LYR):-2.8885
ROE:-37.76%
ROA:-24.01%
PB:8.60
PE(LYR):-24.16

Loading ...

Avidity Biosciences: Promising Outlook for DMD Treatment with Del-Zota and Platform Expansion

TIPRANKS
·
Sep 11

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Consumer Inflation Report

MT Newswires Live
·
Sep 11

Lovesac, Avidity Biosciences, Veritone And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Benzinga
·
Sep 11

S&P 500 Futures Climb In Premarket Trading; Avidity Biosciences, Installed Bldg Products Lag

Dow Jones
·
Sep 11

Avidity Biosciences Shares Slide After Disclosing Public Stock Offering

Dow Jones
·
Sep 11

Avidity Biosciences price target raised to $56 from $54 at BofA

TIPRANKS
·
Sep 11

Avidity Biosciences’ Del-Zota Shows Promising Data in DMD, Justifying Buy Rating and $56 Price Target

TIPRANKS
·
Sep 11

BUZZ-Avidity Biosciences slides on planned $500 mln stock offering

Reuters
·
Sep 11

Avidity Biosciences announces $500M common stock offering

TIPRANKS
·
Sep 11

Avidity Biosciences Announces $500 Million Public Offering of Common Stock to Advance Clinical Programs and Infrastructure Expansion

Reuters
·
Sep 11

Avidity Biosciences Inc - Announces $500 Mln Public Offering

THOMSON REUTERS
·
Sep 11

Raymond James Sticks to Its Buy Rating for Avidity Biosciences (RNA)

TIPRANKS
·
Sep 11

Cantor finds Avidity data highly supportive of del-zota best-in-class potential

TIPRANKS
·
Sep 11

BUZZ-U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy

Reuters
·
Sep 11

Avidity Biosciences Inc : Needham Raises Target Price to $65 From $60

THOMSON REUTERS
·
Sep 10

Avidity Biosciences: Promising Phase 1/2 Trial Results and FDA Agreement Boost Buy Rating

TIPRANKS
·
Sep 10

Avidity Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
Sep 10

BUZZ-Avidity Biosciences rises after positive trial data for muscle wasting drug

Reuters
·
Sep 10

Avidity Says Potential Duchenne Muscular Dystrophy Treatment Shows Disease Reversal in Phase 1/2 Trial

MT Newswires Live
·
Sep 10

BRIEF-Avidity Biosciences' Del-zota Shows Disease Reversal in Key Endpoints

Reuters
·
Sep 10